MARKET

IMNM

IMNM

Immunome Inc
NASDAQ
22.44
-0.97
-4.14%
After Hours: 22.51 +0.07 +0.31% 19:55 02/12 EST
OPEN
24.20
PREV CLOSE
23.41
HIGH
24.25
LOW
22.25
VOLUME
1.24M
TURNOVER
--
52 WEEK HIGH
27.65
52 WEEK LOW
5.15
MARKET CAP
2.48B
P/E (TTM)
-7.5978
1D
5D
1M
3M
1Y
5Y
1D
Shopify upgraded, Coinbase downgraded: Wall Street’s top analyst calls
TipRanks · 22h ago
This Sezzle Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Benzinga · 23h ago
Immunome Initiated at Buy by HC Wainwright & Co.
Dow Jones · 1d ago
Immunome Price Target Announced at $40.00/Share by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Initiates Coverage On Immunome with Buy Rating, Announces Price Target of $40
Benzinga · 1d ago
Immunome: Differentiated Oncology Portfolio and ADC Platform Underpin Buy Rating and $40 Price Target
TipRanks · 1d ago
Immunome initiated with a Buy at H.C. Wainwright
TipRanks · 1d ago
IMMUNOME, INC. <IMNM.O>: H.C. WAINWRIGHT INITIATES COVERAGE WITH BUY RATING
Reuters · 1d ago
More
About IMNM
Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.

Webull offers Immunome Inc stock information, including NASDAQ: IMNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMNM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMNM stock methods without spending real money on the virtual paper trading platform.